Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
31.27
+1.14 (3.78%)
At close: May 12, 2025, 4:00 PM
31.75
+0.48 (1.54%)
After-hours: May 12, 2025, 7:54 PM EDT
Alkermes Employees
Alkermes had 1,800 employees as of December 31, 2024. The number of employees decreased by 300 or -14.29% compared to the previous year.
Employees
1,800
Change (1Y)
-300
Growth (1Y)
-14.29%
Revenue / Employee
$840,983
Profits / Employee
$195,948
Market Cap
5.16B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALKS News
- 11 days ago - Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible - Seeking Alpha
- 11 days ago - Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Alkermes plc Reports First Quarter 2025 Financial Results - PRNewsWire
- 12 days ago - New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) - PRNewsWire
- 25 days ago - Alkermes to Report First Quarter Financial Results on May 1, 2025 - PRNewsWire
- 5 weeks ago - Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference - PRNewsWire
- 5 weeks ago - Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PRNewsWire
- 6 weeks ago - New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PRNewsWire